Pioneering Pharmaceuticals completed a Phase Ib clinical trial in the United States for Freythaen (KX-826).

Guide: Freythan (KX-826) is used to treat ar antagonic, a small molecule used in androgen alfa.
, Which. announced on August 4th that the group had completed a Phase Ib clinical trial in the United States.
F. Furitaen (KX-826) is a potential lysy small molecule AR antagonist developed by the pharmaceutical industry to treat androgen allocated hair loss and is conducting ongoing clinical trials in China and the United States.
Phase Ib clinical trial in the United States was a randomized, double-blind, placebo-controlled, parallel group, and dose-increasing study of healthy male subjects with androgenal hair loss to assess the safety, tolerance, and pharmacokinetics of Freythan (KX-826) after multiple locally increased doses.
recruited a total of 40 healthy male hair loss health subjects for a total of four dose groups, of whom 32 were randomly treated with active drugs and 8 were randomly given placebos in double-blind manners (10 subjects in each dose group, 2 of whom were randomly placed placebos).
the dose levels of local use of Freythan (KX-826) are 2.5 mg, 5 mg, 10 mg and 20 mg.
these Phase Ib clinical trials are progressing smoothly and stable and have not been significantly affected by the current U.S. COVID-19 outbreak.
Forward Pharmaceuticals is analyzing and evaluating data collected in the U.S.-based KX-826 Ib Clinical Trials and expects to determine clinical research reports (CSRs) and release data in the fourth quarter of 2020.
.